FilingSEC EDGAR6-K
Agomab Therapeutics Reports Positive Phase 2a Results for Ontunisertib in FSCD
· SEC accepted
StagePhase 2a Completed, Phase 2b Preparation
Filing content
Agomab reported positive long-term safety and tolerability data from the Phase 2a extension study of ontunisertib and plans to initiate a global Phase 2b trial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…